0.3514

8.96% -0.0346

After Hours: .2328 -0.1186 -33.75%

Virios Therapeutics Inc (VIRI)

Overview News Price History Option Chain Financials Discussions Forecast

Virios Therapeutics Inc stock is currently priced at $0.3514, with a 24-hour trading volume of 531.33K. It has seen a -8.96% decreased in the last 24 hours and a -22.07% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.3921 pivot point. If it approaches the $0.3423 support level, significant changes may occur.

Previous Close:

$0.386

Open:

$0.4095

24h Volume:

531.33K

Market Cap:

$6.77M

Revenue:

Net Income/Loss:

$-5.30M

P/E Ratio:

-0.6389

EPS:

-0.55

Net Cash Flow:

$-4.87M

1W Performance:

-0.99%

1M Performance:

-22.07%

6M Performance:

-52.45%

1Y Performance:

-66.21%

1D Range:

$0.3507

$0.4095

52W Range:

$0.279

$2.42

Virios Therapeutics Inc Stock (VIRI) Company Profile

Name

Virios Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

866 620 8655

Address

44 Milton Avenue, Alpharetta

Employee

Twitter

Next Earnings Date

2024-03-18

Latest SEC Filings

VIRI's Discussions on Twitter

Virios Therapeutics Inc Stock (VIRI) Latest News

Virios Therapeutics Shares Tumble 35% on Stock Offering - MarketWatch

MarketWatch

Virios Therapeutics launches $2.1 million public stock offering By Investing.com - Investing.com

Investing.com

Virios Therapeutics announces proposed public offering of common stock (NASDAQ:VIRI) - Seeking Alpha

Seeking Alpha

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned ... - GlobeNewswire

GlobeNewswire

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

GlobeNewswire Inc.

Research Analysts Set Expectations for Virios Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VIRI) - Defense World

Defense World

Virios Therapeutics Inc Stock (VIRI) Financials Data

Virios Therapeutics Inc (VIRI) Net Income 2024

VIRI net income (TTM) was -$5.30 million for the quarter ending December 31, 2023, a +56.76% increase year-over-year.

Virios Therapeutics Inc (VIRI) Cash Flow 2024

VIRI recorded a free cash flow (TTM) of -$4.87 million for the quarter ending December 31, 2023, a +57.53% increase year-over-year.

Virios Therapeutics Inc (VIRI) Earnings per Share 2024

VIRI earnings per share (TTM) was -$0.28 for the quarter ending December 31, 2023, a +78.63% growth year-over-year.

Virios Therapeutics Inc Stock (VIRI) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Duncan Gregory Scott	CHIEF EXECUTIVE OFFICER	Aug 17 '23	Buy	1.25	25,000	31,245	57,461

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.